165 related articles for article (PubMed ID: 11436421)
1. Cidofovir in the treatment of HPV-associated lesions.
Snoeck R; Andrei G; De Clercq E
Verh K Acad Geneeskd Belg; 2001; 63(2):93-120, discussion 120-2. PubMed ID: 11436421
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells.
Andrei G; Snoeck R; Schols D; De Clercq E
Oncol Res; 2000; 12(9-10):397-408. PubMed ID: 11697818
[TBL] [Abstract][Full Text] [Related]
3. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.
Abdulkarim B; Sabri S; Deutsch E; Chagraoui H; Maggiorella L; Thierry J; Eschwege F; Vainchenker W; Chouaïb S; Bourhis J
Oncogene; 2002 Apr; 21(15):2334-46. PubMed ID: 11948417
[TBL] [Abstract][Full Text] [Related]
4. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III).
Snoeck R; Noel JC; Muller C; De Clercq E; Bossens M
J Med Virol; 2000 Feb; 60(2):205-9. PubMed ID: 10596022
[TBL] [Abstract][Full Text] [Related]
5. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.
Snoeck R; Bossens M; Parent D; Delaere B; Degreef H; Van Ranst M; Noël JC; Wulfsohn MS; Rooney JF; Jaffe HS; De Clercq E
Clin Infect Dis; 2001 Sep; 33(5):597-602. PubMed ID: 11477525
[TBL] [Abstract][Full Text] [Related]
6. Local treatment of HPV-induced skin lesions by Cidofovir.
Stragier I; Snoeck R; De Clercq E; Van Den Oord JJ; Van Ranst M; De Greef H
J Med Virol; 2002 Jun; 67(2):241-5. PubMed ID: 11992585
[TBL] [Abstract][Full Text] [Related]
7. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.
Andrei G; Snoeck R; Piette J; Delvenne P; De Clercq E
Oncol Res; 1998; 10(10):523-31. PubMed ID: 10338155
[TBL] [Abstract][Full Text] [Related]
9. Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions.
Coremans G; Snoeck R
Expert Opin Pharmacother; 2009 Jun; 10(8):1343-52. PubMed ID: 19463071
[TBL] [Abstract][Full Text] [Related]
10. Resolution of recalcitrant human papillomavirus gingival infection with topical cidofovir.
Calista D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Dec; 90(6):713-5. PubMed ID: 11113816
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Johnson JA; Gangemi JD
Antimicrob Agents Chemother; 1999 May; 43(5):1198-205. PubMed ID: 10223936
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
13. Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms.
Mertens B; Nogueira T; Stranska R; Naesens L; Andrei G; Snoeck R
Oncotarget; 2016 Jul; 7(30):47302-47318. PubMed ID: 27331622
[TBL] [Abstract][Full Text] [Related]
14. Intralesional or topical cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV-1-infected patients.
Orlando G; Fasolo MM; Beretta R; Signori R; Adriani B; Zanchetta N; Cargnel A
AIDS; 1999 Oct; 13(14):1978-80. PubMed ID: 10513659
[No Abstract] [Full Text] [Related]
15. The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.
Liekens S; Noppen S; Gijsbers S; Sienaert R; Ronca R; Tobia C; Presta M
Oncotarget; 2015 Mar; 6(7):4633-48. PubMed ID: 25609197
[TBL] [Abstract][Full Text] [Related]
16. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage.
De Schutter T; Andrei G; Topalis D; Naesens L; Snoeck R
BMC Med Genomics; 2013 May; 6():18. PubMed ID: 23702334
[TBL] [Abstract][Full Text] [Related]
17. Cidofovir plasma assays after local injection in respiratory papillomatosis.
Naiman AN; Roger G; Gagnieu MC; Bordenave J; Mathaut S; Ayari S; Nicollas R; Bour JB; Garabedian N; Froehlich P
Laryngoscope; 2004 Jul; 114(7):1151-6. PubMed ID: 15235339
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro.
Hostetler KY; Rought S; Aldern KA; Trahan J; Beadle JR; Corbeil J
Mol Cancer Ther; 2006 Jan; 5(1):156-9. PubMed ID: 16432174
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir.
Liekens S; Neyts J; De Clercq E; Verbeken E; Ribatti D; Presta M
Cancer Res; 2001 Jul; 61(13):5057-64. PubMed ID: 11431341
[TBL] [Abstract][Full Text] [Related]
20. Systemic cidofovir in papillomatosis.
Van Valckenborgh I; Wellens W; De Boeck K; Snoeck R; De Clercq E; Feenstra L
Clin Infect Dis; 2001 Feb; 32(3):E62-4. PubMed ID: 11170974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
